This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

AstraZeneca's Scrappy Defenders Against Pfizer's Billions

Stocks in this article: AZNPFE

NEW YORK (TheStreet) -- Chuka Umunna, the Labour MP from Streatham, U.K., and the Shadow Business Secretary, is an angry man.

What's got him riled is American pharma giant Pfizer's (PFE) transatlantic bid to acquire British drugmaker AstraZeneca (AZN)  in a mammoth $106 billion deal. Umunna has attacked Pfizer's track record in acquisitions as "intellectual asset-stripping" exercises.

Mega-mergers and acquisitions are always saddled with controversy from the day matters become public, and Pfizer's bid to press ahead with the deal despite twice being turned down by its target has set the business world abuzz.

Playing out side-by-side is a political battle between the Conservative-led David Cameron government, which is batting for the deal, and the Labour Party, which sees the loss of U.K. jobs due to the acquisition as a rallying call for action.

The Liberal Democrats, as has increasingly become their lot, are sandwiched somewhere in between, their hearts probably with Labour but mindful of the fact that their own Vince Cable is in the hot seat as the Business Secretary.

Speaking of being sandwiched: Pfizer did its P.R. folks no favors when, in 2011, in a much-criticized move, it shut down its leading R&D center in Sandwich, in the U.K. county of Kent. The company employed 2,400 people at the site and a thriving local economy had mushroomed around the facility.

Tax experts point to another motivation for Pfizer to be looking toward the island nation. If the merger were to go through, Pfizer could make Britain its reporting location for tax purposes, saving a neat $1 billion in taxes.

This move to navigate away from U.S. taxes has also upset a few lawmakers on Capitol Hill. Proposals under consideration in the Senate as well as in Obama's 2015 budget would ban such practices by U.S. companies. No wonder Pfizer wants this deal to go through A.S.A.P.

Pfizer's version of its pursuit of AstraZeneca reads very differently from this talk, though. The company line is that the merger would create the largest pharma company in the world, and it would have greater and faster access to new markets, as well as a global research base.

Aware that such pronouncements are standard fare in such deals, Pfizer has indicated a willingness to protect jobs at AstraZeneca. The trouble is, the way private companies work, it is next to impossible to guarantee such a thing. Umunna, as reported by the more provocative sections of the British media, called these assurances "not worth the paper they are written on."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,168.01 +193.70 1.14%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,549.4880 +0.2620 0.01%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs